AKTX - Akari Therapeutics

-

$undefined

N/A

(N/A)

Akari Therapeutics NASDAQ:AKTX Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

Location: 24 W 40th St Fl 8, New York, 10018-1028, US | Website: akaritx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

63.11B

Cash

4.177M

Avg Qtr Burn

-3.949M

Short % of Float

-

Insider Ownership

37.61%

Institutional Own.

1.53%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nomacopan Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Update

Nomacopan Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 3

Initiation

Phase 2

Update

Nomacopan Details
Atopic Keratoconjunctivitis

Phase 1/2

Update

Nomacopan Details
Geographic atrophy, Eye disease

Phase 1

Initiation

Nomacopan Details
Bullous pemphigoid

Failed

Discontinued